INC Research has acquired AVOS Life Sciences. The new division of INC Research, called AVOS Consulting, will provide strategic, operational and financial analysis to life sciences companies. AVOS will operate as a separate division within the company reporting to the chief executive officer, James Ogle.
“We are very pleased to welcome this esteemed group of experts to the INC Research family,” said Mr. Ogle. “The addition of the team members and their proven analytical tools will provide immediate value to our existing customers and significantly contribute to our alliance partnerships efforts.”
Key executives from AVOS — including Neil MacAllister, Keith Ruark, Kathleen Griffin, and David Ewbank — have expertise providing insights into areas such as healthcare trend assessment, business model development, capital allocation, portfolio optimization, accelerated drug development models and pricing and market access.
“Our understanding of the complex healthcare industry and the deep therapeutic foresight within INC Research is a powerful combination to develop new approaches to global drug development and commercialization efforts,” said Mr. MacAllister, president of AVOS Consulting and executive vice president of INC Research. “For example, we work with customers to reach proof of concept faster and at lower cost while carrying these efficiencies over to the later stages of clinical development.”
In addition to providing consulting services, the AVOS team will support INC Research’s Alliance Partnerships program dedicated to the creation and management of strategic clinical delivery alliances.